Published in Radiology on December 01, 1992
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
MR imaging of therapy-induced changes of bone marrow. Eur Radiol (2006) 1.95
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging (2006) 1.02
Comparison of Technetium-99m-MIBI imaging with MRI for detection of spine involvement in patients with multiple myeloma. BMC Nucl Med (2003) 0.96
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia (2015) 0.86
Solitary plasmacytoma in the thoracic spine. Two case reports. Neurosurg Rev (1998) 0.86
The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia (2014) 0.85
In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow. MAGMA (2007) 0.81
Differences in perfusion parameters between upper and lower lumbar vertebral segments with dynamic contrast-enhanced MRI (DCE MRI). Eur Radiol (2008) 0.79
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol (2001) 10.39
Structure and mechanism of interleukin-1 beta converting enzyme. Nature (1994) 4.44
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res (1994) 4.32
X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell (1995) 3.68
Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med (1997) 3.62
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology (2000) 3.03
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood (2000) 2.87
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol (2010) 2.32
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
The effect of continuous epidural analgesia on cesarean section for dystocia in nulliparous women. Am J Obstet Gynecol (1989) 2.17
A natural history of cleidocranial dysplasia. Am J Med Genet (2001) 2.14
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol (1999) 2.05
Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol (1996) 2.04
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst (1996) 1.99
Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma (2007) 1.96
Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood (1997) 1.95
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology (1994) 1.91
The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab (1992) 1.86
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res (1980) 1.82
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med (1994) 1.75
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol (2004) 1.74
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
The phylogeny of the Schistosomatidae based on three genes with emphasis on the interrelationships of Schistosoma Weinland, 1858. Parasitology (2003) 1.74
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol (1999) 1.72
Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. J Am Coll Surg (1995) 1.66
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65
Uncertainty analysis of absorbed dose calculations from thermoluminescence dosimeters. Med Phys (1993) 1.65
Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer (2000) 1.63
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol (2005) 1.61
Rounded atelectasis and mesothelioma. AJR Am J Roentgenol (1998) 1.60
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res (1999) 1.60
Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol (2005) 1.59
Cancer mortality in Menofeia, Egypt: comparison with US mortality rates. Cancer Causes Control (1999) 1.59
Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. AJR Am J Roentgenol (1995) 1.58
Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet (1997) 1.57
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys (1998) 1.56
Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia (1995) 1.55
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol (1998) 1.54
A randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer. Gastroenterology (2003) 1.54
Extraosseous multiple myeloma: imaging features. AJR Am J Roentgenol (1993) 1.52
Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer (1989) 1.52
2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52
Phylogenies inferred from mitochondrial gene orders-a cautionary tale from the parasitic flatworms. Mol Biol Evol (2000) 1.50
Biochemical analysis of the stress protein response in human oesophageal epithelium. Gut (1997) 1.50
Optimization of prostate biopsy strategy using computer based analysis. J Urol (1997) 1.47
Analysis of clinically occult and mammographically occult breast tumors. AJR Am J Roentgenol (1977) 1.46
Plasma cell granuloma of the nasal cavity treated by radiation therapy. Cancer (1991) 1.45
Bacillus subtilis alkaline phosphatases III and IV. Cloning, sequencing, and comparisons of deduced amino acid sequence with Escherichia coli alkaline phosphatase three-dimensional structure. J Biol Chem (1991) 1.45
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol (1993) 1.44
The changing spectrum of gastroesophageal reflux disease. Eur J Cancer Prev (2002) 1.44
Melphalan therapy for plasma cell myeloma. Blood (1968) 1.43
Pulmonary toxicity from novel antineoplastic agents. Ann Oncol (2005) 1.39
Radiation nephropathy in the rhesus monkey: morphometric analysis of glomerular and tubular alterations. Int J Radiat Oncol Biol Phys (1995) 1.37
Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood (1988) 1.36
Combination chemotherapy for multiple myeloma. Cancer (1972) 1.36
Progressive multifocal leukoencephalopathy: clinical and radiographic features. Ann Neurol (1985) 1.35
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia (2012) 1.34
Sarcoidosis. Typical and atypical thoracic manifestations and complications. Clin Radiol (1970) 1.34
Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein. Cancer (1980) 1.34
Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol (2001) 1.33
Semiquantitative oropharyngeal culture technique. Appl Microbiol (1970) 1.33
Localized and indolent myeloma. Blood (1980) 1.33
Clinical radioimmunodetection of cancer with radioactive antibodies to human chorionic gonadotropin. Science (1980) 1.32
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29
Prognostic factors in multiple myeloma. Cancer (1975) 1.29
Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer (1992) 1.28
Does maintenance therapy keep duodenal ulcers healed? Lancet (1988) 1.28
Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol (1990) 1.28